WO2000018430A3 - Live virus vaccines to protect primates from hiv-1 infection and disease - Google Patents

Live virus vaccines to protect primates from hiv-1 infection and disease Download PDF

Info

Publication number
WO2000018430A3
WO2000018430A3 PCT/US1999/022349 US9922349W WO0018430A3 WO 2000018430 A3 WO2000018430 A3 WO 2000018430A3 US 9922349 W US9922349 W US 9922349W WO 0018430 A3 WO0018430 A3 WO 0018430A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
disease
infection
live virus
virus vaccines
Prior art date
Application number
PCT/US1999/022349
Other languages
French (fr)
Other versions
WO2000018430A2 (en
Inventor
Opendra Narayan
Original Assignee
Univ Kansas Medical Center
Opendra Narayan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas Medical Center, Opendra Narayan filed Critical Univ Kansas Medical Center
Priority to AU62681/99A priority Critical patent/AU6268199A/en
Priority to EP99949907A priority patent/EP1109575A2/en
Priority to CA002345959A priority patent/CA2345959A1/en
Publication of WO2000018430A2 publication Critical patent/WO2000018430A2/en
Publication of WO2000018430A3 publication Critical patent/WO2000018430A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The instant invention teaches pathogenic SHIV which cause AIDS in monkeys, the construction of virus for use in vaccines against pathogenic SHIV and HIV-1, and methods for prophylactic and therapeutic vaccination to prevent or inhibit HIV-1 infection and/or disease. The instant invention teaches the construction of modified live virus for use in vaccines against HIV-1, and methods for prophylactic and therapeutic vaccination to prevent or inhibit HIV-1 infection and/or disease. The instant invention teaches the use of viral DNA vaccines for the treatment and prevention of HIV infection and/or disease.
PCT/US1999/022349 1998-09-29 1999-09-28 Live virus vaccines to protect primates from hiv-1 infection and disease WO2000018430A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU62681/99A AU6268199A (en) 1998-09-29 1999-09-28 Live virus vaccines to protect primates from hiv-1 infection and disease
EP99949907A EP1109575A2 (en) 1998-09-29 1999-09-28 Live virus vaccines to protect primates from hiv-1 infection and disease
CA002345959A CA2345959A1 (en) 1998-09-29 1999-09-28 Live virus vaccines to protect primates from hiv-1 infection and disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10214398P 1998-09-29 1998-09-29
US60/102,143 1998-09-29

Publications (2)

Publication Number Publication Date
WO2000018430A2 WO2000018430A2 (en) 2000-04-06
WO2000018430A3 true WO2000018430A3 (en) 2000-07-06

Family

ID=22288338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022349 WO2000018430A2 (en) 1998-09-29 1999-09-28 Live virus vaccines to protect primates from hiv-1 infection and disease

Country Status (4)

Country Link
EP (1) EP1109575A2 (en)
AU (1) AU6268199A (en)
CA (1) CA2345959A1 (en)
WO (1) WO2000018430A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929937C (en) * 2012-09-11 2020-01-07 The Regents Of The University Of California Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050070A1 (en) * 1997-05-02 1998-11-12 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050070A1 (en) * 1997-05-02 1998-11-12 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
G ALDROVANDI ET AL: "Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice", JOURNAL OF VIROLOGY, vol. 3, no. 70, March 1996 (1996-03-01), pages 1505 - 1511, XP002077808 *
HAGA T ET AL: "A new approach to AIDS research and prevention: the use of gene-mutated HIV -1/ SIV chimeric viruses for anti- HIV -1 live-attenuated vaccines", MICROBIOLOGY AND IMMUNOLOGY, vol. 42, no. 4, 1998, pages 245 - 251, XP000891768 *
JOAG S V ET AL: "Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS.", JOURNAL OF VIROLOGY, vol. 72, no. 11, November 1998 (1998-11-01), pages 9069 - 9078, XP002134842 *
LETVIN N L ET AL: "Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus.", JOURNAL OF VIROLOGY, vol. 69, no. 7, July 1995 (1995-07-01), pages 4569 - 4571, XP002134843 *
LOHMAN B L ET AL: "Mucosal immunization with a live, virulence- attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques", JOURNAL OF MEDICAL PRIMATOLOGY, vol. 23, no. 2/03, February 1994 (1994-02-01), pages 95 - 101, XP002108261 *
R DESROSIERS: "HIV with multiple gene deletion as a live attenuated vaccine for AIDS", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 8, August 1992 (1992-08-01), pages 1457, XP002077807 *

Also Published As

Publication number Publication date
CA2345959A1 (en) 2000-04-06
WO2000018430A2 (en) 2000-04-06
EP1109575A2 (en) 2001-06-27
AU6268199A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
CA2243570A1 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
EP1820853A3 (en) Recombinant influenza viruses for vaccines and gene therapy
WO1995000638A3 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
DE60110822D1 (en) PREPARING FOR IMMUNIZING AGAINST THE AIDS VIRUS
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
HK1044799A1 (en) Immunoligically significant herpes simplex virus antigens
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2004045529A3 (en) West nile virus vaccine
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2005097179A3 (en) Stabilised tat antigen and the use thereof for anti-hiv vaccination
WO2000018430A3 (en) Live virus vaccines to protect primates from hiv-1 infection and disease
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
AU4111600A (en) The use of gssg reductase for the therapy and prophylaxis of hiv infected patients
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
WO2003045428A3 (en) Use of a technically modified cell as a vaccine for treating tumoral disease
NO20013101L (en) Outer surface proteins, their genes and their use
WO2002046214A3 (en) Immunomodulatory protein derived from the yaba monkey tumor virus
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2345959

Country of ref document: CA

Ref document number: 2345959

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999949907

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00263/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 09806162

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999949907

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999949907

Country of ref document: EP